Abstract:
Despite recent advances that have clarified the etiologies of alcohol-associated liver disease (ALD), the cellular
and molecular alterations that lead to progressive liver damage are only partially understood. Furthermore, there
are currently no FDA-approved therapies that block, or reverse ALD progression. Thus, it is urgent that we
identify cellular and molecular mechanisms that contribute to progressive liver damage, to improve disease
prognosis, and identify new treatment targets and procedures that alleviate or even prevent ALD.
Heavy alcohol consumption affects all tissues, but it causes the greatest damage to the liver. This is because
alcohol (ethanol or EtOH) is primarily metabolized in the liver to generate toxic products (acetaldehyde,
superoxide, and hydroxyl radicals) that, with continued drinking, damage and impair the structure and function
of membrane-bound organelles, including the ER, mitochondrion, and the lysosome. The latter organelle
degrades nearly all macromolecules in eukaryotic cells. Our objective is to identify specific alterations induced
by EtOH metabolite(s) that cause lysosome damage in hepatocytes and Kupffer cells (resident liver
macrophages), and which leads to parenchymal cell death and inflammatory signaling, respectively.
Lysosomes have a crucial role in cellular quality control, as they recycle obsolete proteins and dysfunctional
organelles, including damaged lysosomes. If cells do not repair/remove damaged lysosomes, they will continue
to leak their proteolytic enzymes to trigger cell death and provoke inflammatory signaling by Kupffer cells.
We and others previously reported that chronic ethanol (EtOH) consumption causes faulty lysosome biogenesis
and lysosomal membrane instability. Here, we show exciting new pilot data indicating that chronic EtOH
consumption by both humans and rodents causes lysosomal membrane damage and subsequent leakage of
lysosomal cathepsin(s) (and other hydrolases) that contribute to liver cell injury. Furthermore, such damage
releases lysosomal membrane components into the circulation, which may be prognostic markers of liver injury.
Our pilot data, presented herein, suggest that primary and/or secondary EtOH metabolites damage lysosomes
in hepatocytes and Kupffer cells, inducing cathepsin leakage which contribute to cell death and inflammation.
These novel observations support our hypothesis that chronic EtOH oxidation damages lysosomes, causing
leakage of cytotoxic lysosomal hydrolases, thereby, contributing to liver injury and inflammation. To test
our hypothesis, we propose the following Specific Aims:
In Aim 1 we will define the mechanisms of EtOH-induced lysosome damage that incite hepatocyte injury.
In Aim 2 we will investigate the mechanisms of EtOH-induced lysosome damage that incite inflammatory
signaling in Kupffer cells.
We anticipate that the outcome of this research will reveal novel mechanisms by which EtOH oxidation promotes
the progression of liver pathology by damaging lysosomes.